Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00238628 | A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer | PHASE1 | COMPLETED | 12 | — | — | Apr 1, 2004 | Dec 1, 2005 | Jul 20, 2010 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Bexarotene | DRUG | - |
| Iressa | DRUG | - |
Inclusion Criteria:- Patients must have histologically or cytologically confirmed NSCLC which is stage IIIB with malignant pleural effusion or stage IV and have failed therapy with at least a standard first line chemotherapy regimen, or be intolerant of standard chemotherapy. * Patients may have no...